1. Scrip
  2. >>Therapy Areas
  3. >>Genitourinary

How Sweden's Calliditas Built Up Its US Presence And Development Portfolio

Approval Submission Of Lead Candidate Expected This Quarter

 
• By John Davis

Interview: delivering on its US business strategy during the COVID-19 pandemic has required a focus on communication, according to Calliditas CEO Renee Aguiar-Lucander.  

View of Gamla Stan in the Old Town of Stockholm
The Old Town Of Stockholm • Source: Shutterstock

Calliditas Therapeutics AB planned the commercialization of its first rare disease product, Nefecon (budesonide), in the US, and expanded its development pipeline through its first major product candidate acquisition , as its coped with last year’s COVID-19-related travel restrictions and changing business processes. 

Looking back, CEO Renee Aguiar-Lucander is relieved the Stockholm, Sweden-based company began executing its commercialization strategy relatively early. “We started in late 2018, beginning of 2019, so I’ve met the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Genitourinary

More from Therapy Areas

New Vaccine Framework Avoided Worst-Case Scenario, Analysts Say

 
• By Joseph Haas

The new US FDA vaccine guidelines introduced on 20 May might cause financial woes for Moderna, but overall vaccine makers should not be as impacted as feared.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

 
• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.